160 related articles for article (PubMed ID: 17106249)
1. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer.
Landen CN; Merritt WM; Mangala LS; Sanguino AM; Bucana C; Lu C; Lin YG; Han LY; Kamat AA; Schmandt R; Coleman RL; Gershenson DM; Lopez-Berestein G; Sood AK
Cancer Biol Ther; 2006 Dec; 5(12):1708-13. PubMed ID: 17106249
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.
Landen CN; Chavez-Reyes A; Bucana C; Schmandt R; Deavers MT; Lopez-Berestein G; Sood AK
Cancer Res; 2005 Aug; 65(15):6910-8. PubMed ID: 16061675
[TBL] [Abstract][Full Text] [Related]
3. Liposomal siRNA for ovarian cancer.
Mangala LS; Han HD; Lopez-Berestein G; Sood AK
Methods Mol Biol; 2009; 555():29-42. PubMed ID: 19495686
[TBL] [Abstract][Full Text] [Related]
4. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.
Halder J; Kamat AA; Landen CN; Han LY; Lutgendorf SK; Lin YG; Merritt WM; Jennings NB; Chavez-Reyes A; Coleman RL; Gershenson DM; Schmandt R; Cole SW; Lopez-Berestein G; Sood AK
Clin Cancer Res; 2006 Aug; 12(16):4916-24. PubMed ID: 16914580
[TBL] [Abstract][Full Text] [Related]
5. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.
Merritt WM; Lin YG; Spannuth WA; Fletcher MS; Kamat AA; Han LY; Landen CN; Jennings N; De Geest K; Langley RR; Villares G; Sanguino A; Lutgendorf SK; Lopez-Berestein G; Bar-Eli MM; Sood AK
J Natl Cancer Inst; 2008 Mar; 100(5):359-72. PubMed ID: 18314475
[TBL] [Abstract][Full Text] [Related]
6. Sustained small interfering RNA delivery by mesoporous silicon particles.
Tanaka T; Mangala LS; Vivas-Mejia PE; Nieves-Alicea R; Mann AP; Mora E; Han HD; Shahzad MM; Liu X; Bhavane R; Gu J; Fakhoury JR; Chiappini C; Lu C; Matsuo K; Godin B; Stone RL; Nick AM; Lopez-Berestein G; Sood AK; Ferrari M
Cancer Res; 2010 May; 70(9):3687-96. PubMed ID: 20430760
[TBL] [Abstract][Full Text] [Related]
7. Dual targeting of EphA2 and FAK in ovarian carcinoma.
Shahzad MM; Lu C; Lee JW; Stone RL; Mitra R; Mangala LS; Lu Y; Baggerly KA; Danes CG; Nick AM; Halder J; Kim HS; Vivas-Mejia P; Landen CN; Lopez-Berestein G; Coleman RL; Sood AK
Cancer Biol Ther; 2009 Jun; 8(11):1027-34. PubMed ID: 19395869
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis.
Chakravarty D; Roy SS; Babu CR; Dandamudi R; Curiel TJ; Vivas-Mejia P; Lopez-Berestein G; Sood AK; Vadlamudi RK
Clin Cancer Res; 2011 Apr; 17(8):2250-9. PubMed ID: 21421858
[TBL] [Abstract][Full Text] [Related]
9. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.
Nick AM; Stone RL; Armaiz-Pena G; Ozpolat B; Tekedereli I; Graybill WS; Landen CN; Villares G; Vivas-Mejia P; Bottsford-Miller J; Kim HS; Lee JS; Kim SM; Baggerly KA; Ram PT; Deavers MT; Coleman RL; Lopez-Berestein G; Sood AK
J Natl Cancer Inst; 2011 Nov; 103(21):1596-612. PubMed ID: 21957230
[TBL] [Abstract][Full Text] [Related]
10. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.
Shen H; Rodriguez-Aguayo C; Xu R; Gonzalez-Villasana V; Mai J; Huang Y; Zhang G; Guo X; Bai L; Qin G; Deng X; Li Q; Erm DR; Aslan B; Liu X; Sakamoto J; Chavez-Reyes A; Han HD; Sood AK; Ferrari M; Lopez-Berestein G
Clin Cancer Res; 2013 Apr; 19(7):1806-15. PubMed ID: 23386691
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.
Nishimura M; Jung EJ; Shah MY; Lu C; Spizzo R; Shimizu M; Han HD; Ivan C; Rossi S; Zhang X; Nicoloso MS; Wu SY; Almeida MI; Bottsford-Miller J; Pecot CV; Zand B; Matsuo K; Shahzad MM; Jennings NB; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Calin GA
Cancer Discov; 2013 Nov; 3(11):1302-15. PubMed ID: 24002999
[TBL] [Abstract][Full Text] [Related]
12. Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors.
Wang J; Lu Z; Yeung BZ; Wientjes MG; Cole DJ; Au JL
J Control Release; 2014 Mar; 178():79-85. PubMed ID: 24462901
[TBL] [Abstract][Full Text] [Related]
13. Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model.
Iizuka K; Jin C; Eshima K; Hong MH; Eshima K; Fukushima M
Drug Des Devel Ther; 2018; 12():673-683. PubMed ID: 29636601
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
15. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors.
Gunaratne PH; Pan Y; Rao AK; Lin C; Hernandez-Herrera A; Liang K; Rait AS; Venkatanarayan A; Benham AL; Rubab F; Kim SS; Rajapakshe K; Chan CK; Mangala LS; Lopez-Berestein G; Sood AK; Rowat AC; Coarfa C; Pirollo KF; Flores ER; Chang EH
Cancer; 2019 Jul; 125(14):2409-2422. PubMed ID: 31012964
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA).
Wagner MJ; Mitra R; McArthur MJ; Baze W; Barnhart K; Wu SY; Rodriguez-Aguayo C; Zhang X; Coleman RL; Lopez-Berestein G; Sood AK
Mol Cancer Ther; 2017 Jun; 16(6):1114-1123. PubMed ID: 28265009
[TBL] [Abstract][Full Text] [Related]
17. Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells.
Palanca-Wessels MC; Booth GC; Convertine AJ; Lundy BB; Berguig GY; Press MF; Stayton PS; Press OW
Oncotarget; 2016 Feb; 7(8):9561-75. PubMed ID: 26840082
[TBL] [Abstract][Full Text] [Related]
18. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA.
Villares GJ; Zigler M; Wang H; Melnikova VO; Wu H; Friedman R; Leslie MC; Vivas-Mejia PE; Lopez-Berestein G; Sood AK; Bar-Eli M
Cancer Res; 2008 Nov; 68(21):9078-86. PubMed ID: 18974154
[TBL] [Abstract][Full Text] [Related]
19. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
[TBL] [Abstract][Full Text] [Related]
20. PEGylated DC-Chol/DOPE cationic liposomes containing KSP siRNA as a systemic siRNA delivery Carrier for ovarian cancer therapy.
Lee J; Ahn HJ
Biochem Biophys Res Commun; 2018 Sep; 503(3):1716-1722. PubMed ID: 30049442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
